Abstract:Backgrounds: Elucidation of peptide-receptor pairs is a prerequisite for many studies in the neuroendocrine, endocrine, and neuroscience fields. Recent omics analyses have provided vast amounts of peptide and G protein-coupled receptor (GPCR) sequence data. GPCRs for homologous peptides are easily characterized based on homology searching, and the relevant peptide-GPCR interactions are also detected by typical signaling assays. In contrast, conventional evaluation or prediction methods, including high-throughput reverse-pharmacological assays and tertiary structure-based computational analyses, are not useful for identifying interactions between novel and omics-derived peptides and GPCRs. Summary: Recently, an approach combining machine learning-based prediction of novel peptide-GPCR pairs and experimental validation of the predicted pairs have been shown to breakthrough this bottleneck. A machine learning method, logistic regression for human class A GPCRs and the multiple subsequent signaling assays led to the deorphanization of human class A orphan GPCRs, namely, the identification of 18 peptide-GPCR pairs. Furthermore, using another machine learning algorithm, the support vector machine (SVM), the peptide descriptor-incorporated SVM was originally developed and employed to predict GPCRs for novel peptides characterized from the closest relative of vertebrates, Ciona intestinalis Type A ( Ciona robusta ). Experimental validation of the predicted pairs eventually led to the identification of 11 novel peptide-GPCR pairs. Of particular interest is that these newly identified GPCRs displayed neither significant sequence similarity nor molecular phylogenetic relatedness to known GPCRs for peptides. Key Messages: These recent studies highlight the usefulness and versatility of machine learning for enabling the efficient, reliable, and systematic identification of novel peptide-GPCR interactions.

Machine-Learning-Guided Peptide Drug Discovery: Development of GLP-1 Receptor Agonists with Improved Drug Properties

Machine learning trims the peptide drug design process to a sweet spot

Impact of Machine Learning-Associated Research Strategies on the Identification of Peptide-Receptor Interactions in the Post-Omics Era

Combining mass spectrometry and machine learning to discover bioactive peptides

Transformative Target-Based Approaches

Polypharmacy through Phage Display: Selection of Glucagon and GLP-1 Receptor Co-agonists from a Phage-Displayed Peptide Library

Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors

Machine learning for antimicrobial peptide identification and design

Machine learning in preclinical drug discovery

Improved design and screening of high bioactivity peptides for drug discovery

Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency

An integrated platform approach enables discovery of potent, selective and ligand-competitive cyclic peptides targeting the GIP receptor

Deep learning for advancing peptide drug development: Tools and methods in structure prediction and design

Machine learning-guided discovery and design of non-hemolytic peptides

The latest trends in peptide drug discovery and future challenges

Allostery Illuminated: Harnessing AI and Machine Learning for Drug Discovery

Applications of machine learning in drug discovery and development

Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist

Machine Learning Advances in Predicting Peptide/Protein‐Protein Interactions Based on Sequence Information for Lead Peptides Discovery

De novo Design of G Protein-Coupled Receptor 40 Peptide Agonists for Type 2 Diabetes Mellitus Based on Artificial Intelligence and Site-Directed Mutagenesis

Binding sites and design strategies for small molecule GLP-1R agonists